Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Rhea-AI Summary

Olema Pharmaceuticals (NASDAQ: OLMA) announced that its CEO, Sean P. Bohen, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2021, at 12 p.m. ET. The discussion will be moderated by Arlinda Lee, a Biotechnology Analyst at Canaccord Genuity. Investors can access a live webcast of the event in the Investors & Media section on Olema's website, with a replay available later. Olema is dedicated to developing targeted therapies for women’s cancers, including its lead candidate, OP-1250, currently in clinical trials.

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity.

A live webcast of the event will be accessible in the Investors & Media section of Olema’s website. A replay of the webcast will be available.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Investor Contact:
ir@olema.com

Media Contact:
Sheryl Seapy, Real Chemistry
sseapy@realchemistry.com
949-903-4750

FAQ

What is the date and time of the Canaccord Genuity conference where OLMA will be represented?

The Canaccord Genuity Horizons in Oncology Virtual Conference featuring Olema Pharmaceuticals will take place on April 15, 2021, at 12 p.m. ET.

Who is moderating Olema Pharmaceuticals' session at the conference?

The session will be moderated by Arlinda Lee, Ph.D., Managing Director and Biotechnology Analyst at Canaccord Genuity.

How can I access the live webcast of Olema's conference participation?

The live webcast can be accessed in the Investors & Media section of Olema's website.

What is Olema Pharmaceuticals focusing on in their research?

Olema Pharmaceuticals focuses on discovering and developing targeted therapies for women’s cancers.

What is Olema's lead product candidate and its current status?

Olema's lead product candidate is OP-1250, which is currently being evaluated in a Phase 1/2 clinical trial for ER-positive breast cancer.